• 
• 
• 

FDA News and Drug Updates

Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer

First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

New Indications Approved by the FDA in 2018 for Oncology Drugs

Adverse Effects

View All Adverse Effects Articles

Immunotherapy

CAR T-Cell Therapy Fills Unmet Needs in Leukemia and Lymphoma

Wayne Kuznar

Genomic Markers of Response Improve Patient Selection for Immune Checkpoint Inhibitor Therapy

Wayne Kuznar

CAR T-Cell Therapy Associated with Unique, Acute Adverse Events Requiring Vigilant Monitoring

Wayne Kuznar

Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer

Phoebe Starr

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

View All Immunotherapy Articles

Conference Correspondent

Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?

The Importance of Compassion: Perspective From a Lifelong Patient

Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer

Addressing the Second Victim Phenomenon

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

View All Conference Correspondent Articles

Most Popular Articles

Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer

Loretta Fala, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals, Prostate Cancer

FDA Approvals of Novel Brand-Name Prescription Cancer Drugs in 2018

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals

Welcome to the Fourth Annual Oncology Guide to New FDA Approvals

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals

New Indications Approved by the FDA in 2018 for Oncology Drugs

Dalia Buffery, MA, ABD

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals

Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

2019 Fourth Annual Oncology Guide to New FDA Approvals - FDA Approvals, Melanoma